 |
|
|
| |
Baseline and Emergent Genotypic and Phenotypic Results in HIV-1-Infected, Heavily Treatment-Experienced (HTE) Participants Meeting Protocol-Defined Virologic Failure (PDVF) Criteria Through Week 96 in the Fostemsavir (FTR) Phase 3 BRIGHTE Study
|
| |
| |
EACS 2019 Nov 6-9 Basel
Reported by Jules Levin
P. Ackerman1, M. Gartland2, S. Chabria1, F. Mannino3, L. Garside4, R. Kustra1, A. Clark5, A. Pierce2, M. Krystal1, C. Llamoso1, M. Lataillade1
1ViiV Healthcare, Branford, United States, 2ViiV Healthcare, Research Triangle Park, United States, 3GlaxoSmithKline, Upper Providence, United States, 4GlaxoSmithKline, London, United Kingdom, 5ViiV Healthcare, London, United Kingdom
|
| |
|
|
|
|
|
